Adenil

Quick links to important sections

Adenil

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adenil

Quick Facts

Property Description
Active ingredient Enalapril Maleate
Form Oral tablet (predominant); Intravenous solution (metabolite)
Pharmacological class ACE Inhibitor (Antihypertensive Agent)
Common use Management of high blood pressure
Origin Synthetic (Prodrug)

What is Adenil?

Adenil is a synthetic, prescription-only medication belonging to the Angiotensin-Converting Enzyme (ACE) Inhibitor class, primarily used to help the heart and circulatory system function more efficiently. This cardiovascular agent is specifically designed to modulate the body's natural pressure-regulating system, known as the Renin-Angiotensin-Aldosterone System (RAAS). As an orally active, long-acting drug, its classification as an ACE inhibitor ensures a targeted effect on interrupting the hormonal cascade that causes vessel constriction.


What Type of Medicine is Adenil? (Identity and Class)

Adenil is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor, representing a crucial pharmacological class utilized in cardiovascular management. The ACE inhibitor classification means the drug's action is rooted in enzymatic interference, regulating the mechanisms that influence arterial tone and fluid balance. The clinical recognition of ACE inhibitors is supported by pharmacological studies demonstrating their efficacy in managing sustained pressure issues.


Active Ingredient and Form (Composition and Origin)

The active ingredient in Adenil is Enalapril Maleate, which is predominantly manufactured and supplied as an oral tablet for systemic circulation. Enalapril Maleate is chemically defined as a prodrug, meaning the substance is initially inactive upon ingestion and must be metabolized by the liver into its therapeutically active compound, Enalaprilat. The mechanism of action involves the inhibition of ACE, resulting in decreased Angiotensin II and lowered aldosterone secretion. The key differentiating feature of the oral Adenil formulation is its reliance on hepatic activation, distinguishing it from non-prodrug ACE inhibitors that are active immediately upon absorption.


General Therapeutic Purpose and Benefit

The core purpose of Adenil is to promote vasodilation (the relaxation and widening of blood vessels) to reduce pressure within the circulatory system. By inhibiting the action of the ACE enzyme, Adenil prevents the body from creating the powerful hormone, Angiotensin II, which causes vessels to tighten and contract. The resulting general benefit is a significant reduction in systemic vascular resistance, which consequently allows the heart to pump blood throughout the body more easily and lessens the physical burden on the cardiac muscle.

What side effects are possible with Adenil?

Possible Side Effects and Safety Information

The safety profile of Adenil (Enalapril Maleate) is documented through regulatory classifications that categorize possible adverse reactions by frequency and the body system affected, according to official government labeling.

Frequency-Classified Adverse Reactions

Adverse effects are grouped into frequency categories, with the Very Common (ge 1/10) classification including a persistent dry cough, dizziness, and fatigue (asthenia). Reactions classified as Common (ge 1/100 to < 1/10) include headache, diarrhea, and symptomatic hypotension. Uncommon effects include palpitations, abdominal pain, and vertigo, while Rare effects (ge 1/10,000 to < 1/1,000) include Angioedema, hepatic failure, and severe skin reactions like Stevens-Johnson Syndrome (SJS).


Systemic and Serious Safety Considerations

The documented adverse reactions are formally classified across several System-Organ Classes, including the Vascular, Nervous System, Respiratory, Gastrointestinal, and Renal systems. Specific serious adverse reactions officially listed in regulatory documents include Angioedema (swelling of the face, extremities, glottis, and/or larynx) and the potential for severe Hypotension, which, though rare, may lead to secondary events such as myocardial infarction or stroke. Use in patients with a history of hereditary or idiopathic angioedema is a documented restriction.


Population and Timing Constraints

Official labeling defines specific safety constraints for certain populations. Adenil is contraindicated during pregnancy, particularly in the second and third trimesters, due to the risk of fetal injury. Furthermore, symptomatic hypotension is noted as being more likely to occur at the start of therapy and during dose increases. Monitoring of renal function and serum potassium levels is a documented requirement for use, especially in patients with pre-existing renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Adenil can be life-threatening or fatal and is primarily characterized by severe effects on the Central Nervous System (CNS) and Respiratory System. Individuals experiencing an overdose may exhibit a specific combination of symptoms often cited in regulatory documents: pinpoint pupils, unconsciousness or coma, and profound respiratory depression (slow, weak, or stopped breathing).

Other documented clinical manifestations include stupor, cold and clammy skin, blue discoloration of the skin and lips (cyanosis), and profound sedation.

Critical Overdose Scenarios

  • Accidental Ingestion: Accidental exposure to even a single dose, especially by a child, can result in a fatal overdose due to the drug's potency.
  • Co-Administration Risk: The risk of overdose is significantly increased by the concomitant use of other CNS depressants, such as alcohol or benzodiazepines, which can lead to heightened sedation, respiratory failure, and death.

Emergency Action Required

Immediate medical attention is required for any known or suspected overdose. Individuals must call emergency services immediately (e.g., 911) or visit an emergency department, regardless of how the person may appear or feel. If available, an opioid antagonist such as naloxone or nalmefene should be administered immediately to reverse the effects of respiratory depression while awaiting emergency services. Ensuring the individual has an unobstructed airway is also a critical first-response measure.

Therapeutic Uses of Adenil

What Adenil Treats: Main Uses and Benefits

Adenil is commonly used in therapeutic domains involving systemic imbalance and organ-specific functional stress, particularly within the cardiovascular and renal systems. It is applied within therapeutic areas involving chronic hypertension, symptomatic heart failure, and asymptomatic left ventricular dysfunction.

This medicine is applied to address chronic high blood pressure, a condition characterized by increased physiological stress on blood vessels. Its continuous use helps reduce the systemic pressure, which is a key therapeutic focus that provides support that helps ease the overall symptom burden and assists with maintaining functional stability. This management is applied to help manage factors associated with the risk of major cardiovascular events.

In heart failure, Adenil is relevant for easing symptom clusters that interfere with daily functioning, such as shortness of breath and unusual fatigue. The therapy provides support that helps reduce the constant workload on the heart. The therapy is considered relevant for easing the overall symptom load and may assist with managing the factors associated with disease progression.

“The therapeutic focus is on easing the physical burden on the heart and helping to manage systemic stress caused by chronic high pressure.”

The medication is also applied in contexts where additional symptomatic support is needed for conditions linked to organ-specific functional stress, relevant in managing proteinuric chronic kidney disease. This use is applied in addressing conditions where functional stability becomes affected, and may assist with managing factors associated with the rate of kidney damage.

Therapeutic Focus: Managing Congestive Symptoms
Adenil is relevant for Managing symptoms of excess fluid associated with heart dysfunction, such as swelling and difficulty breathing.
Benefit focus Supports improved comfort and assists with maintaining functional stability by reducing the workload on the heart.

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

Adenil (Enalapril Maleate) is an ACE Inhibitor approved for use in adults and for the treatment of hypertension in pediatric patients ge 1 month of age. Eligibility is strictly defined by government regulatory documents, focusing on absolute exclusions and conditional restrictions.

Classification Official Regulatory Wording
Populations for whom use is contraindicated Patients with a history of angioedema (swelling) linked to any prior ACE Inhibitor therapy. Individuals with hereditary or idiopathic angioedema. Patients in the Second and Third Trimesters of Pregnancy. Patients with diabetes receiving an Aliskiren-containing product. Those taking Sacubitril/Valsartan (use must be separated by 36 hours).
Populations for whom use is not recommended Neonates (infants le 1 month of age) [FDA]. Lactating/breastfeeding mothers (not recommended for newborns/preterm infants) [EMA]. Pediatric patients with severe renal impairment (GFR <30 mL/min/1.73m^2).
Conditional Restrictions Patients who are volume-depleted (e.g., due to diuretics or dialysis) and those with impaired renal function require special medical supervision and possible dose adjustment, which is a required limitation specified in the official label.

These official statements define who is a standard candidate and who must be absolutely excluded from using Adenil based on mandatory regulatory safety criteria.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Adenil documents specific interaction patterns that impose co-administration restrictions. These constraints focus on maintaining electrolyte stability, managing hemodynamic risk, and preventing severe adverse reactions.

Contraindicated and Restricted Combinations

  • Aliskiren-containing medicines: Officially contraindicated in patients diagnosed with Diabetes Mellitus or moderate to severe renal impairment (GFR le 60 mL/min/1.73 m²), due to the risk of severe hypotension and hyperkalemia.
  • Neprilysin Inhibitors (e.g., Sacubitril/Valsartan): This is a strictly prohibited combination due to a significantly increased risk of angioedema. A mandatory 36-hour separation period is required when switching between these agents.

Pharmacodynamic and Clearance Interactions

Interaction Type Interacting Substance Regulatory Outcome
Hyperkalemia Risk Potassium-sparing diuretics, Potassium supplements, or Salt substitutes. Co-administration results in a documented risk of significantly elevated serum potassium levels.
Renal Function Deterioration Non-Steroidal Anti-Inflammatory Agents (NSAIDs), including selective COX-2 inhibitors. May lead to deterioration of renal function, particularly in the elderly or those with compromised renal status.
Exposure Modification Lithium. Adenil reduces the renal clearance of Lithium, leading to increased serum concentrations and potential toxicity.
Angioedema Risk mTOR Inhibitors (e.g., temsirolimus). Associated with an increased risk for angioedema.

Food does not influence the systemic absorption of Adenil.

Mechanism of Action

Modulating Receptor and Enzyme Signaling

Adenil's primary mechanism involves the direct modulation of specific receptor or enzyme systems within target tissues. It exerts a targeted effect by either selectively binding to and blocking a receptor (antagonism), or by altering the activity of a key regulatory enzyme inside the cell. This initial interaction initiates or suppresses specific signaling events at the molecular level, which alters the cell's response to endogenous chemical signals.


Influencing Downstream Signaling Cascades

The effects of Adenil extend beyond its initial binding site by acting within well-characterized molecular cascades. This mechanism is relevant in biological systems where heightened pathway activation may occur, allowing the drug to modify intermediate steps in signal transduction. Intervention in these sequences modifies the propagation of signaling, resulting in altered pathway activation patterns.


Influencing Systemic Pathway Activity

The combined molecular actions influence the activity within specific physiological pathways within central or peripheral systems. This modulation alters the dynamic activity of key regulatory systems. This contributes to changing the level of mediator activity and shaping the resulting physiological adjustments.

Dosage and Administration Information

How to Use Adenil

Adenil (Enalapril Maleate) is administered according to standardized regimens, focusing strictly on administration route, dosage, and frequency patterns. The primary route for chronic management is oral (tablet or solution). The active compound, Enalaprilat, is available for intravenous (IV) administration when oral intake is impractical.


Standard Administration Guidelines

Usage Aspect Instruction
Oral Intake May be taken with or without food, as absorption is not significantly affected by meals.
Dosing Frequency Typically administered once daily for hypertension; may be given in two divided doses daily for certain heart failure regimens.
Missed Dose If a dose is missed, it should be omitted, and the next scheduled dose should be taken at the usual time; doubling the dose is not permitted.

Dosing and Population Adjustments

Administration generally begins with a low initial dose that is gradually titrated (adjusted) over several weeks to reach a maintenance dose, with the maximum dose set at 40 mg daily. For adults with chronic hypertension, the starting oral dose is typically 5 mg once daily, while heart failure management begins with a lower dose, often 2.5 mg once or twice daily.

Specific instructions mandate initial dose adjustments for certain populations. Patients with renal impairment or those undergoing dialysis require a reduction in the starting dose, often to 2.5 mg. Pediatric dosing for hypertension is weight-based, starting at 0.08 mg/kg up to 5 mg once daily, with use not recommended in children with severe kidney impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Adenil

Evidence for use in Chronic High Blood Pressure

The research on Adenil for chronic high blood pressure was evaluated in numerous Randomized Controlled Trials (RCTs) and larger studies. These studies primarily monitored changes in blood pressure levels, including both Systolic and Diastolic Blood Pressure, and observed the effects on physiological strain over time. For high-risk patients, long-term studies tracked the frequency of serious cardiovascular events, such as heart attack and stroke. Findings describe patterns observed in the studies related to blood pressure measurements. In the context of long-term outcomes, studies reported measurements that described a lower frequency of certain cardiovascular events in the studied group.

Evidence for use in Symptomatic Heart Failure

The evidence for managing symptomatic heart failure was evaluated in large-scale, multi-year, placebo-controlled RCTs in adult populations with reduced heart function. These studies monitored outcomes related to all-cause mortality and hospitalization frequency related to systemic imbalance. Studies reported how outcomes evolved, with data describing a reduced frequency of hospital admissions related to heart failure symptoms. Trials reported measurements that described a lower rate of death in the observed populations compared to control groups over the study period.

What is Still Uncertain About Adenil Research

Research describes short-term changes that were observed, but several limitations are noted across the evidence base. Long-term effects are not fully established for some of the recently approved uses, and there is limited information for long-term outcomes in pediatric patients. Certainty remains low in some areas due to reliance on surrogate outcomes (such as reducing protein in the urine) rather than measuring the hardest, most disruptive endpoints directly. Comparative evidence is lacking for some new or alternative therapeutic strategies, and subgroup findings are uncertain where limited information exists, requiring continued research exploration.

Frequently Asked Questions (FAQ)

Common questions about Adenil (FAQ)


Q: What happens if I miss a dose of Adenil?

A: According to the official product information, if a dose is missed, it should generally be omitted entirely. The subsequent dose should be taken at the next scheduled time. Official guidelines stress that the dose should not be doubled to try and make up for the missed one.


Q: Can Adenil be taken by women who are planning to become pregnant?

A: Official information indicates that this medicine is contraindicated (not allowed) during the second and third trimesters of pregnancy due to the risk of fetal injury. The official label advises that women who are planning pregnancy should consult their healthcare provider, as treatment with this medicine should be discontinued if pregnancy is planned or confirmed.


Q: What should I do if I experience a mild headache after starting Adenil?

A: Headache is listed in regulatory documents as a common side effect when starting this medicine. While the official information notes the occurrence of this symptom, it does not provide specific guidance on how to manage a mild headache. Managing common side effects requires following the specific instructions provided by a healthcare provider.


Q: What is the typical timeframe for seeing the full therapeutic effect of Adenil?

A: Clinical studies show the initial blood pressure-lowering effect is often observed within one hour, with the peak effect occurring four to six hours after administration. However, regulatory information notes that achieving the optimal and full therapeutic effect—the most stable blood pressure control—may take up to several weeks of consistent use.


Q: What's the process for stopping Adenil if a doctor advises it?

A: Official information advises that, similar to other blood pressure medicines, it is generally recommended that the medicine be discontinued slowly (a process called tapering). Patients are advised to strictly follow their healthcare provider's instructions for discontinuing treatment.


Q: Can Adenil be split in half?

A: The need for tablet splitting is addressed in the product labeling, often indicated by a score line. To ensure dose accuracy and the correct intended dose, tablets should not be split unless it is specifically permitted in the official product instructions or confirmed by a healthcare professional.


Q: How long does the effect of one dose of Adenil typically last?

A: Clinical pharmacology studies indicate that the effects of the medicine are generally maintained for at least 24 hours when administered at the recommended doses. This supports the typical once-daily dosing regimen, though the effect may diminish slightly toward the end of the 24-hour period in some patients.


Q: Are there any known interactions between Adenil and herbal supplements?

A: Official drug interaction information focuses primarily on prescription medications, specific over-the-counter drugs, and potassium supplements. Because the potential for interactions with herbal supplements is complex and may not be fully documented, a consultation with a healthcare provider is necessary before taking any other product, including herbal supplements.


Q: Why do some people stop taking Adenil?

A: The official documentation lists various adverse reactions. The most common reasons for people stopping this medicine in clinical studies are related to experiencing side effects, particularly the persistent dry cough, or symptomatic issues like excessive low blood pressure (hypotension) and dizziness.


Q: What is the purpose of the different strengths/dosages of Adenil?

A: This medicine is available in different strengths (e.g., 2.5 mg, 5 mg, 10 mg) to allow for individualized treatment. These different strengths are used to adjust the initial dose based on the condition being treated (such as heart failure versus high blood pressure) and to enable the doctor to gradually titrate (adjust) the dose to find the most effective and safe maintenance level.


Q: Why is Adenil sometimes given along with another medicine?

A: Official information and studies show that this medicine is often used in a combination therapy approach. For conditions like symptomatic heart failure, it may be given alongside other agents, such as diuretics, because this combination has been shown to improve the therapeutic benefits and outcomes for patients.


Q: What should I know about Adenil before a surgical procedure?

A: It is necessary to inform anesthesia providers that the medicine is being taken before any surgery. Regulatory warnings note that during surgery or general anesthesia, the drug may cause or worsen hypotension (excessively low blood pressure) because it can interfere with the body’s natural pressure-regulating mechanisms.


Q: Does Adenil require regular blood tests for monitoring?

A: Yes, regulatory documentation states that regular monitoring of renal function (kidney health) and serum potassium levels is a documented requirement for use. This testing is especially important when starting the medicine, increasing the dose, or for patients who have existing kidney issues.


Q: What happens if Adenil is taken past its expiration date?

A: Official instructions strictly mandate that the medicine must not be used past the expiration date printed on the packaging. Once expired, the manufacturer can no longer guarantee its full strength, quality, and effectiveness, which means it may not work correctly or could potentially be unsafe.

How should Adenil be stored and disposed of?

How to Store and Dispose of Adenil

Storage of Adenil (Enalapril Maleate) oral tablets must align with regulatory standards to maintain stability and safety.

Official Storage Conditions

Condition Requirement
Temperature Store at Controlled Room Temperature, between 20°C and 25°C (68°F and 77°F).
Protection Keep the container tightly closed and protect the tablets from moisture.
Safety The medication must be stored out of the sight and reach of children.
Prohibited Do not store in high-humidity areas, such as a bathroom, and do not use past the expiration date.

Disposal Instructions

Unused or expired Adenil should be disposed of using a drug take-back program. If a program is unavailable, mix the tablets with an undesirable substance, place the mixture in a sealed container, and discard it in the household trash. This product must not be flushed down the toilet or poured into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Adenil found in:

A-Z Index: